Indian generic giant Ranbaxy said Wednesday it has spent over $300 million to overhaul its operations and ensure no repeat of drug safety violations that led to a multi-million dollar US fine. Last week, New Delhi-based Ranbaxy pleaded guilty in the United States to charges of making and distributing adulterated drugs made at its two Indian plants of Paonta Sahib and Dewas, agreeing to a $500-million settlement.
"Ranbaxy is a different company today," Ranbaxy chief executive Arun Sawhney said in a statement, adding all the company products "in the global market are safe". "We have made significant improvements in the way we conduct our business to ensure greater quality control and have made investments of over $300 million in our manufacturing facilities to install state-of-the-art technologies," he added.
The US settlement ended eight years of criminal and civil investigations into the company, which is now majority-owned by Japan's Daiichi Sankyo. Daiichi bought a controlling stake in Ranbaxy in 2008 in a $4.6-billion transaction to gain entry into the fast-expanding global copycat drugs market. But the Japanese firm saw the value of its investment plummet as a result of regulatory reverses for Ranbaxy Laboratories in the United States, the world's biggest drug market. Daiichi said in a separate statement it continued to support Ranbaxy in its efforts to "correct the conduct of the past" which led to the investigations by the US Department of Justice and the US Food and Drug Administration.